Lonza Group Ltd acquires Genentech manufacturing facility in Vacaville, California from Roche Holding AG for $1.2bn.
Lonza Group Ltd, a Swiss healthcare manufacturing firm, has agreed to acquire Roche Holding AG's Genentech manufacturing facility in Vacaville, California for $1.2bn. The acquisition will increase Lonza's large-scale biologics manufacturing capacity and complement its existing site on the East Coast. Lonza plans to invest around $500m to upgrade the facility and expand capabilities to support the next generation of mammalian biologics therapies. The transaction is expected to close in the second half of 2024.
March 20, 2024
17 Articles